Last month, our team proudly wore red to show our deep commitment to finding new treatments for blood cancers. #BloodCancerAwarenessMonth #BloodCancer #CancerResearch
关于我们
At Ichnos Glenmark Innovation (IGI), our mission is to provide curative therapies that extend and improve lives. IGI is an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage biotech company developing multispecifics? in oncology, and its parent, Glenmark Pharmaceuticals Ltd. (Glenmark), with the aim to accelerate new drug discovery in cancer treatment. IGI combines Ichnos' research and development proficiencies in novel biologics with those of Glenmark’s in new small molecules to continue developing cutting-edge therapy solutions that treat hematological malignancies and solid tumors. Harnessing the combined proficiency of over 150 scientists and a robust pipeline of novel molecules, this collaboration will leverage the capabilities of its three global centers of innovation spread across the USA, Switzerland and India to propel Innovation. We believe in the power of collaboration to drive innovation. Being an alliance, we ourselves embody this belief. Collaboration that helps us combine forces of expertise, technology, speed and reach between Ichnos and Glenmark as well as among other stakeholders. Collaboration that helps us transform the world of oncology by creating novel cutting-edge therapeutics, faster. Collaboration that kindles new hope for oncology patients, their families and healthcare professionals.
- 网站
-
https://iginnovate.com/
Ichnos Glenmark Innovation的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- New York，NY
- 类型
- 私人持股
- 创立
- 2019
地点
Ichnos Glenmark Innovation员工
-
Richard Van Ewijk
BioTech | BioPharma | GxP | CDMO | Consultant | Vice President Global Quality, IMP QP & HSE at Ichnos Sciences
-
Maria Pihlgren Bosch
-
Michael Dyson
-
Daniel E. Rasmussen
Head of CMC Operations & Portfolio Management, Degree in Business Development (MBD) from Copenhagen Business School
动态
-
We are pleased to announce a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of The National Institutes of Health (U.S.). Under the CRADA, IGI and NCI will collaborate on evaluating IGI's proprietary Cbl/b small molecule, GRC 65327, in Triple Negative Breast Cancer (TNBC).?? ? NCI's Stanley Lipkowitz, MD, PhD, will build on his early research on Cbl/b’s role as a negative regulator of the adaptive immune system. His lab's work in late-stage TNBC complements IGI's program to advance GRC 65327 in other solid tumors.? ? Read more: https://bit.ly/4dr8qJq #ClinicalResearch #Innovation #Oncology #BreastCancer?
-
-
?? Join us to accelerate a cure for multiple myeloma at the Multiple Myeloma Research Foundation - MMRF’s Walk/Run in NYC or virtually. More here: https://lnkd.in/gtUCHPX2 #MMRF
September reminds us of our deep commitment to battling blood cancers — a cause that resonates profoundly with us at Ichnos Glenmark Innovation and Glenmark Pharmaceuticals. It’s a month dedicated to raising awareness about blood cancers, and I am proud to share our commitment to this cause through our participation in the MMRF Walk for Multiple Myeloma. Blood Cancer Awareness Month is not just a time to reflect, but an opportunity to act and make a difference. ? On October 5th, we will be walking in New York City, and we invite all of you to join us in this vital effort. If you’re not in New York, you can still participate virtually from October 5th to October 11th. ? Your involvement will directly impact the fight against multiple myeloma and help us move closer to a cure. Let’s come together, make every step count, and show our unwavering commitment to this important cause. Join us or donate at: https://lnkd.in/g4bUZTjT
-
-
September turns red each year for Blood Cancer Awareness Month. Blood cancers – which include leukemia, lymphoma, and multiple myeloma – are some of the world’s most prevalent and dangerous types of cancer. At IGI, we’re focused on advancing our two clinical programs for the potential treatment of multiple myeloma. Find out more: https://bit.ly/3B9KwVs #Hematology #Cancer #Oncology #ThisIsBloodCancer
-
-
Check out this Fierce Biotech article by Darren Incorvaia on our trispecific antibody for multiple myeloma and preclinical findings published in Nature Cancer. Cyril Konto, M.D., President, Executive Director & CEO, discusses how ISB 2001 works and demonstrates the value of the BEAT platform. Article here: https://bit.ly/4gwXyMT #biotechnology #drugdiscovery #oncology
-
OPEN POSITIONS AT IGI – NYC - Clinical Scientist, Associate Director - Data Management, Associate Director - Program Development Team Lead, Sr / Exec Director - Clinical Trial Management, Director All roles are - Exempt; not eligible for overtime. - Hybrid schedule (3 days in the NYC office) No relocation or immigration sponsorship is being offered at this time. Candidate must be located within the tri-state area (NY, NJ, CT). PLEASE REACH OUT TO THE IGI HR US TEAM VIA EMAIL [email protected] Ichnos Sciences, Inc. & Ichnos Glenmark Innovation are equal opportunity employers, and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, sexual orientation, gender identity, disability status, height, weight, protected veteran status, or any other characteristic protected by law.
-
-
We’re thrilled to announce our research publication in Nature Cancer on ISB 2001, IGI’s innovative BCMA x CD38 x CD3 trispecific T-cell engager for refractory/relapsed multiple myeloma. The publication highlights preclinical findings demonstrating that ISB 2001 can potentially overcome myeloma cell escape mechanisms. The data show superior killing potency of multiple myeloma tumor cells by ISB 2001 when compared to several bispecific therapies and combination of therapies. IGI plans to release the preliminary clinical results of the ongoing Phase 1 dose-escalation study at an upcoming conference. The article is available at https://lnkd.in/e4tKsEc3 #CancerResearch #Cancer #Myeloma Nature Portfolio
-
-
What exactly are multispecific antibodies – or multispecifics?? Learn more about the advantages of multispecifics at https://bit.ly/3SHzDAh #biotechnology #biologics #antibodies #partnering #biopharma
-
Highlights of our most recent quarter include an oral presentation on our novel, clinical-stage multispecific? asset ISB 2001 at AACR in April 2024. Read more about how we continue to advance our innovations in oncology in our quarterly update: https://bit.ly/3YIa0D3 #Biotechnology #CancerResearch #AACR2024
-